<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticholinergic (antimuscarinic) therapy for drying secretions* at the end of life</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticholinergic (antimuscarinic) therapy for drying secretions* at the end of life</h1>
<div class="graphic"><div class="figure"><div class="ttl">Anticholinergic (antimuscarinic) therapy for drying secretions* at the end of life</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1_left">Agents</td> <td class="subtitle1_left">Adult dose</td> </tr> <tr class="divider_bottom divider_top"> <td>Glycopyrrolate (glycopyrronium)<sup>[1,2]</sup> <ul class="decimal_heading"> <li>Preferred over scopolamine</li> </ul> </td> <td> <p>0.2 mg SubQ every 4 to 6 hours as needed</p> <p class="indent1">OR</p> <p>0.2 mg SubQ once; followed after 30 minutes by continuous SubQ or IV infusion of 0.6 to 1.2 mg/day</p> <p class="indent1">OR</p> 0.1 mg SL every 6 hours as needed (use commercially available or compounded oral liquid)</td> </tr> <tr class="divider_bottom"> <td>Scopolamine transdermal patch</td> <td>Apply one 1.5 mg (1 mg/3 days) patch behind ear for up to 72 hours; if needed for more than 72 hours, remove old patch and place new one behind other ear.</td> </tr> <tr class="divider_bottom"> <td>Scopolamine (hyoscine<sup>¶</sup>) BUTYLbromide<sup>[2-4]</sup> <ul class="decimal_heading"> <li>If glycopyrrolate is not available, preferred over scopolamine hydrobromide and scopolamine transdermal patch</li> <li>Not available in United States</li> </ul> SEE NOTE</td> <td> <p>20 mg SubQ every 4 to 6 hours as needed</p> <p class="indent1">OR</p> 20 mg SubQ once; followed after 30 minutes by SubQ or IV continuous infusion of 20 to 60 mg/day</td> </tr> <tr> <td>Scopolamine (hyoscine<sup>¶</sup>) HYDRObromide<sup>[1-3]</sup> <ul class="decimal_heading"> <li>Not available in United States</li> </ul> SEE NOTE</td> <td> <p>0.3 mg orally or sublingually every 4 to 6 hours as needed</p> <p class="indent1">OR</p> <p>0.4 mg SubQ every 4 to 8 hours as needed</p> <p class="indent1">OR</p> 0.4 mg SubQ once; followed after 30 minutes by continuous SubQ or IV infusion of 1.2 to 1.6 mg/day</td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>NOTE:</strong> Scopolamine <em>butylbromide</em> and scopolamine <em>hydrobromide</em> formulations are not equivalent and are <strong>not</strong> interchangeable on a milligram-to-milligram basis. Scopolamine <em>butylbromide</em> salt is a quaternary derivative with fewer CNS effects (eg, less risk of delirium and agitation) compared with scopolamine <em>hydrobromide</em> and patch (base) formulations.</div><div class="graphic_footnotes">SubQ: subcutaneous; IV: intravenous.<br/>* Also known as "death rattle." Anticholinergic (antimuscarinic) effects may contribute to patient discomfort (eg, dryness, urinary retention) and do not dry secretions already present. Refer to UpToDate topics on palliative care for guidance on use and limitations of anticholinergic therapy.<br/>¶ Scopolamine is also known as "hyoscine" in many countries.</div><div class="graphic_reference">Data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.<br/>References: 
<ol>
<li>Hugel H, Ellershaw J, Gambles M. Respiratory Tract Secretions in the Dying Patient: A Comparison between Glycopyrronium and Hyoscine Hydrobromide. J Palliat Med 2006; 9:279.</li>
<li>Wilcock A, Howard P, Charlesworth S (Eds). Palliative Care Formulary, 7th ed, Pharmaceutical Press. © 2020. p.11-20.</li>
<li>Bennett M, Lucas V, Brennan M, et al. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 2002; 16:369.</li>
<li>Hughes A, Wilcock A, Corcoron R, et al. Audit of three antimuscarinic drugs for managing retained secretions. Palliat Med 2000; 14:221.</li></ol></div><div id="graphicVersion">Graphic 81557 Version 22.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
